Article Title: FDA again rejects Atara, Pierre Fabre’s cell therapy for Epstein-Barr virus
Publication Date: January 12, 2026
The FDA has recently rejected, for the second time, a T cell therapy for a grave transplant complication related to Epstein-Barr virus, as reported on January 12, 2026. The therapy, known as tabelecleucel or tab-cel, is a product of Atara Biotherapeutics and is specifically developed to treat patients with Epstein-Barr virus.
Atara Biotherapeutics and its partner Pierre Fabre have been targeting Epstein-Barr Virus (EBV)-associated post-transplant complications, a critical area with unmet healthcare demands. The latest rejection by FDA comes as a major setback for these two firms that anticipated tab-cel to turn around the landscape for EBV patients.
While the details of the regulatory agency’s concerns have not been publicized, this decision implies a significant delay in the drug’s approval trajectory unless Atara can swiftly address the FDA’s objections. Concern rises for investors of Atara Biotherapeutics in light of this repeated FDA rejection, as it leaves the company in a dire situation where their lead product lacks regulatory approval. As a result, the probable deferred market entry of tab-cel has become a critical risk to consider.
This development also represents a loss of potential market opportunity in the sector of EBV-associated post-transplant treatments. With limited alternatives available, the need for reliable and effective treatment strategies is urgent and the space is ripe for competition. Therefore, other biotech firms developing similar products may see this as an opportunity to seize.
In the volatile landscape of biotech and pharmaceutical industry, changes can hit companies unexpectedly and with full force, as with the case of Atara Biotherapeutics and Pierre Fabre. To stay abreast of these market trends, monitor FDA decisions and understand the implications, continue to rely on Industry Informant as your dependable source of biotech industry intelligence.
